Form D · Pharmaceuticals
Secura Bio, Inc.
San Diego, CA · CIK 0001771442
Offering snapshot reported Apr 1, 2019 · SEC filing
- Reported sold
- $50M Offering amount: $90M
- Investors reported
- 2 Form D · investor count
- Minimum accepted
- $10M Reported outside-investor minimum
- First sale
- Mar 1, 2019 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Apr 1, 2019 | Initial | $50,000,000 | No comparison | 2 | SEC filing |
Offering details
- Securities
- Debt
- Exemptions
- 06b
- Duration over one year
- Yes
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-336108
$90M represents a debt offering of which $50M in initial notes is outstanding and $40M remains to be issued as delayed draw notes, but there is a commitment by an investor to purchase.
Source: Form D, filed Apr 1, 2019. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Juan Estruch | Executive |
| Joseph Limber | Director, Executive |
| Brett Lund | Director, Executive |
| Mark Spring | Director, Executive |
Issuer details
Industry: Pharmaceuticals (See others in industry)
Address:
11988 El Camino Real Suite 650
San Diego, CA, 92130
San Diego, CA, 92130